Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-23 extended-release tablets for primary insomnia (Phase III)
CTR20140447Phase 3Active
- Sponsor
- Shandong Bainuo Pharmaceutical
- Start
- Jul 2014
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lactobacillus casei BL23 in Insomnia, sponsored by Shandong Bainuo Pharmaceutical. Started Jul 2014; status: active.
02
Drugs
lactobacillus casei BL23
03
Conditions
Insomnia
Beyond the preview
Go deeper on CTR20140447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140447.